# A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

> **NCT07656727** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioAge Labs, Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Obesity and Cardiovascular Risk

## Interventions

- **DRUG:** Oral BGE-102
- **DRUG:** Oral Placebo Matching BGE-102

## Key facts

- **NCT ID:** NCT07656727
- **Lead sponsor:** BioAge Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-11
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07656727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07656727, "A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07656727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*